Obviously this segment of research and development is dynamic...

Obviously this segment of research and development is dynamic with continuous change, with new developments forced by positive research outcomes - and Clarity is at the forefront of the Medical Research. The latest update to that above-referred article is:
"Molecules. 2022 Mar; 27(5): 1501. Published online 2022 Feb 23. doi: 10.3390/molecules27051501PMCID: PMC8912090PMID: 3526860067Cu Production Capabilities: A Mini Review"

In particular I refer to Clarity's agreement with Northstar, as quoted from the latest Annual Report:
"Our commercial-scale copper-67 supplier, NorthStar Medical Radioisotopes (NorthStar), is now routinely producing the radioisotope using their large-scale, highly efficient, environmentally preferable electron accelerator technology. NorthStar has now supplied copper-67 for clinical trial participants, with the first participant of the highest dose escalation cohort in the CL04 theranostic trial in neuroblastoma, an aggressive childhood cancer, receiving Northstar’s copper-67.
"NorthStar complements our ongoing supply from the Idaho Accelerator Center, which has been supplying us copper-67 for all of our pre-clinical and clinical development over the last 8 years."